Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: This study investigates whether mercaptobenzimidazoles act as thiolates in inhibiting copper corrosion. To this end, we examined three mercaptobenzimidazole derivatives — 2-mercaptobenzimidazole (SH-BimH), 2-mercapto-1-methylbenzimidazole (SH-BimMe), and 2-(methylthio)benzimidazole (Me-S-BimH) — as corrosion inhibitors for copper in 3 wt% NaCl solution using a combined experimental and computational approach. Me-S-BimH has a thiol group (single bondSH) replaced by a methylthio group (single bondSCH ), which should prevent the formation of surface thiolates. In contrast, SH-BimMe has the same molecular formula as Me-S-BimH, but its methyl group does not cap the thiol group. Corrosion experiments reveal that after 1 h of immersion, Me-S-BimH is considerably less effective than SH-BimH and SH-BimMe at inhibiting copper corrosion. However, after 100 h of immersion, Me-S-BimH performs comparably to SH-BimH and SH-BimMe. This delayed effectiveness suggests that a molecular transformation activates Me-S-BimH over time. To explore this phenomenon, we performed a detailed DFT study of potential chemical transformations of adsorbed Me-S-BimH. Most transformations are exothermic, but only molecular deprotonation and Csingle bondS bond cleavage between the azole ring and the methylthio group exhibit sufficiently low activation barriers to occur at room temperature. Similar deprotonation and Csingle bondS bond cleavage reactions occur also for SH-BimH and SH-BimMe, leading to more strongly bound species than their intact molecular forms. Due to these transformations, Me-S-BimH and SH-BimH eventually result in the same strongly bound species, while SH-BimMe forms an analogous species. These findings may explain why, over time, all three compounds exhibit similar corrosion inhibition characteristics, and highlight the importance of chemical transformations of adsorbed molecules in corrosion inhibition.
Ključne besede: copper, corrosion inhibition, electrochemical measurements
Objavljeno v DiRROS: 25.08.2025; Ogledov: 351; Prenosov: 188
Celotno besedilo (4,41 MB)
Gradivo ima več datotek! Več...

Ključne besede: modeling, microstructure evolution, drawing, cryogenic cooling
Objavljeno v DiRROS: 22.08.2025; Ogledov: 394; Prenosov: 186
Celotno besedilo (3,18 MB)
Gradivo ima več datotek! Več...

Ključne besede: Directed Energy Deposition, powder stream, DEM, CFD, coupled simulation
Objavljeno v DiRROS: 22.08.2025; Ogledov: 402; Prenosov: 180
Celotno besedilo (744,85 KB)
Gradivo ima več datotek! Več...

Ključne besede: ZK61 Mg alloys, extrusion, microstructure, mechanical properties
Objavljeno v DiRROS: 22.08.2025; Ogledov: 507; Prenosov: 238
Celotno besedilo (7,98 MB)
Gradivo ima več datotek! Več...

Povzetek: Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy (CAR-T) but has rarely been reported following therapy with immune checkpoint inhibitors (ICI). We present a clinical case of severe CRS after ICI therapy for advanced non-small-cell lung cancer (NSCLC). After the third cycle of ipilimumab and nivolumab the patient presented with fever, hypotension and somnolence, leading to acute respiratory failure, acute kidney and hepatic failure, capillary leak syndrome, requiring ICU (intensive care unit) care. She recovered after receiving tocilizumab and steroid therapy. Subsequently, we found 17 clinical cases of advanced NSCLC patients in peer review, experiencing CRS as an adverse event of treatment with ICI. We review those cases in detail and compare the similarities and outcomes. Conclusion: CRS is a serious, life-threatening complication that is rare after ICI therapy for solid cancers but becoming increasingly frequent since ICI therapies are broadening indications. When presented with clinical symptoms, considering CRS is crucial, as early recognition is key to timely intervention and favorable outcome for the patient.
Ključne besede: on-small-cell lung cancer, immune checkpoint inhibitors, cytokine release syndrome, immune- related adverse events, case report
Objavljeno v DiRROS: 22.08.2025; Ogledov: 396; Prenosov: 202
Celotno besedilo (1,32 MB)
Gradivo ima več datotek! Več...